A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

  • Breast Cancer
Trial Status:


This trial runs in
  • Auckland
  • Christchurch
Trial Identifier:

NCT02738970 BO30185

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta. Exposure between SC Perjeta and IV Perjeta will be compared using a compilation of pharmacokinetic (PK) parameters such as area under the concentration-time curve (AUC), maximum serum concentration (Cmax), time of maximum concentration (Tmax), and serum trough concentration (Ctrough). Part 2 is designed to confirm the dosing regimen in women with EBC on the basis of safety, tolerability, and PK assessments.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT02738970 , BO30185 Trial Identifier
      Trastuzumab, Pertuzumab Treatments
      Early Breast Cancer Condition
      Official Title

      A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer

      Eligibility Criteria

      All Gender
      ≥ 18 Years & ≤ 45 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Part 1: Healthy male volunteers 18 to 45 years of age
      • Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%)
      • Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m^2)
      • Part 1: Normal, intact skin without tattoos or lesions in the injection area
      • Part 2: Females at least 18 years of age
      • Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0
      • Part 2: Previously treated, non-metastatic carcinoma of the breast
      • Part 2: Baseline LVEF at least 55%
      • Part 2: Negative pregnancy test and use of adequate contraceptive measures among women of childbearing potential
      Exclusion Criteria
      • Part 1: Positive urine test for drugs of abuse
      • Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
      • Part 1: Cardiac disease including hypertension or hypotension
      • Part 1: Lower extremity edema
      • Part 1: Any clinically relevant history of systemic disease
      • Part 1: History of breast cancer
      • Part 1: Chronic corticosteroid use
      • Part 1: Receipt of IV antibiotics within 7 days prior to enrollment
      • Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening
      • Part 2: Significant cumulative exposure to anthracyclines
      • Part 2: Serious cardiac disease including uncontrolled hypertension
      • Part 2: Poor hematologic, renal, or hepatic function
      • Part 2: Pregnant or lactating women
      • Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV
      • Part 2: Chronic corticosteroid use
      • Part 2: Receipt of IV antibiotics within 7 days prior to enrollment

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now